Financial Performance - The total revenue for the year ended December 31, 2025, was RMB 64,380,000, a decrease of 13.6% compared to RMB 74,542,000 in 2024[4] - The gross profit for the same period was RMB 30,950,000, down from RMB 33,212,000, reflecting a gross margin decline[4] - The operating loss from continuing operations increased to RMB 7,555,000, compared to RMB 3,348,000 in the previous year[4] - The net loss attributable to the owners of the company for the year was RMB 6,564,000, compared to RMB 8,699,000 in 2024, indicating a reduction in losses[6] - The basic and diluted loss per share from continuing operations was RMB (6.89) for 2025, slightly improved from RMB (7.16) in 2024[7] - The total comprehensive loss for the year was RMB 5,554,000, compared to RMB 9,645,000 in the previous year, showing an improvement[5] - The company experienced a net loss of RMB 8,671,000 before tax for 2025, compared to a loss of RMB 7,454,000 in 2024, indicating ongoing financial challenges[25] - For the fiscal year 2025, the company reported a pre-tax loss of RMB 6,564,000, compared to a loss of RMB 8,699,000 in 2024, indicating an improvement of approximately 24.5% year-over-year[35] Revenue Breakdown - The revenue from funeral services in other regions (China, Hong Kong, and Taiwan) was RMB 63,762,000, while the revenue from Vietnam's funeral services was RMB 616,000, indicating a significant reliance on the other regions for revenue generation[23][27] - The total revenue from the Chinese market was RMB 62,415,000 in 2025, down from RMB 67,035,000 in 2024, reflecting a decrease of approximately 6.4%[27] - The revenue from Taiwan decreased to RMB 1,220,000 in 2025 from RMB 2,188,000 in 2024, showing a decline of approximately 44.3%[27] - Revenue from the Hong Kong business decreased by approximately 86.0%, falling to around RMB 745,000 from RMB 5,319,000, largely due to the completion of a major delivery of biotechnology instruments in the previous year[53] - The revenue from biotechnology and other businesses was RMB 618,000 in 2025, a slight increase from RMB 4,500,000 in 2024, indicating a shift in focus towards this segment[23][24] Operational Costs - Administrative expenses rose to RMB 37,984,000 from RMB 34,716,000, indicating increased operational costs[4] - The total cost of inventory recognized as an expense for 2025 was RMB 9,290,000, compared to RMB 12,935,000 in 2024, showing a significant decrease of approximately 28.5%[29][30] - The total depreciation and amortization expenses for 2025 amounted to RMB 6,713,000, a decrease from RMB 7,226,000 in 2024, reflecting a reduction of about 7.1%[29][30] - The company reported a total of RMB 1,067,000 in interest expenses for 2025, a slight decrease from RMB 1,473,000 in 2024, reflecting a reduction of about 27.5%[28] - The company incurred a total income tax expense of RMB 2,948,000 for 2025, down from RMB 2,817,000 in 2024, which represents an increase of approximately 4.6%[31] Asset and Liability Management - Non-current assets decreased from RMB 54,248 thousand in 2024 to RMB 46,494 thousand in 2025, a decline of approximately 14%[8] - Current assets decreased from RMB 196,378 thousand in 2024 to RMB 182,934 thousand in 2025, a decline of about 7%[8] - Total liabilities decreased from RMB 133,611 thousand in 2024 to RMB 128,392 thousand in 2025, a reduction of approximately 4%[9] - Net current assets decreased from RMB 62,767 thousand in 2024 to RMB 54,542 thousand in 2025, a decline of around 13%[8] - Total equity decreased from RMB 103,534 thousand in 2024 to RMB 98,195 thousand in 2025, a decrease of about 5%[9] Strategic Focus and Future Plans - The company plans to continue focusing on cost management and operational efficiency to improve future performance[3] - The company aims to diversify its business model to ensure sustainable growth by expanding into the "low-altitude economy" and life sciences sectors[53] - The company is actively deploying resources in strategic emerging industries to ensure sustainable growth and has transitioned from a traditional funeral service provider to a high-tech enterprise with independent R&D capabilities[48] - The company has established a non-wholly owned subsidiary, Bat Shark Future (Guangdong) Aviation Technology Co., Ltd., to lead the development of new energy unmanned ground effect vehicles, achieving a significant milestone with the successful first flight test of its first-generation aircraft FU1[48] - The company is focusing on accelerating the commercialization process of new products and enhancing collaboration with industry partners to maximize shareholder returns[49] Discontinued Operations - The company has ceased operations related to the sale of cemetery and tombstone services in Vietnam, impacting comparative figures[11] - The company successfully completed the sale of its entire equity interest in Junqun Development Limited for a cash consideration of HKD 10,000,000, effectively terminating its operations in Vietnam[66] - Losses from discontinued operations in Vietnam narrowed from approximately RMB 2,648,000 in the previous year to about RMB 61,000 this year, demonstrating the effectiveness of the strategic shift[66] - The revenue from discontinued operations for the period from January 1 to August 15, 2025, is RMB 616,000, compared to RMB 401,000 for the entire year of 2024, marking a 53.7% increase[43] - The operating loss from discontinued operations for the period is RMB (445,000), a significant improvement from RMB (2,633,000) in 2024, indicating an 83.1% reduction in losses[43] Corporate Governance and Compliance - The company has complied with the corporate governance code based on the GEM listing rules, with a focus on high-quality board and transparency to shareholders[109] - No significant violations of applicable laws and regulations have occurred during the year[111] - The audit committee, consisting of three independent non-executive directors, has reviewed the audited consolidated financial statements and confirmed compliance with applicable accounting standards[114] Investment and Financial Management - The group maintained a cautious financial management strategy and did not utilize any financial instruments for hedging purposes during the year[72] - The group is actively monitoring economic conditions and acknowledges potential changes that may impact financial performance[73] - The group has established a strategic partnership with a professional investment firm specializing in venture capital and emerging industry consulting to enhance asset identification and management capabilities[77] - The group’s current bank borrowings were approximately RMB 992,000, with non-current borrowings at RMB 143,000 and RMB 240,000 respectively[70] - The net debt-to-equity ratio remains prudent at approximately 57.2% as of December 31, 2025, down from 58.7% in 2024, ensuring financial flexibility for strategic investment opportunities[82]
中国生命集团(08296) - 2025 - 年度业绩